by 
The global Ribonucleic Acid (RNA) Markers Market is engaged in discovery and development of RNA biomarkers that can aid disease diagnosis, prognosis, and treatment assessment in clinical settings. RNA biomarkers offer potential advantages over protein biomarkers as they may provide a more complete picture of cellular regulatory networks and health status. Advances in genomics, molecular biology, epigenetics, and computational analysis continue to reveal new connections between genes, ncRNAs, and disease. Ribonucleic acid (RNA) markers are emerging as useful clinical biomarkers for a wide range of diseases. Messenger RNA (mRNA) and long noncoding RNA (lncRNA) levels can serve as indicators of physiological or pathophysiological conditions. The global Ribonucleic Acid (RNA) Markers Market is estimated to be valued at US$ 347.6 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The global Ribonucleic Acid (RNA) Markers market is expected to be driven by increasing R&D investment in RNA biomarker discovery. Biopharmaceutical companies and research institutes are investing heavily to identify novel RNA biomarkers and develop clinical assays. For instance, in March 2022, the Government of Canada announced an investment of US$ 15 million in RNA biomarker research at the University Health Network (UHN) in Toronto, Canada. This funding will aid in discovery and validation of RNA biomarkers that can help diagnose diseases early and advance precision medicine approaches. Moreover, growing applications of RNA biomarkers in oncology for cancer screening, prognosis, and therapeutic response monitoring is also expected to fuel market growth over the forecast period. RNA biomarkers hold strong potential to revolutionize cancer management. However, technical limitations in robust and reproducible measurement of RNA biomarkers in complex clinical samples continue to hamper complete realization of their clinical utility. Ongoing improvements in RNA isolation techniques and development of sensitive detection platforms will help address these challenges.
Segment Analysis
The global RNA markers market is segmented by product type, technology, application, end user, and region. Based on product type, the RNA markers market is segmented into sample preparation kits, assay kits, probes/primers. The sample preparation kits segment dominates the market as they have high usage for RNA isolation, purification, and quantification. By technology, the market is segmented into microarrays, RT-PCR, sequencing. The RT-PCR segment dominates as it is the gold standard technique for measuring gene expression and quantifying transcript levels.
PEST Analysis
Political: The growth of the RNA markers market is positively influenced by favorable government policies and increasing funding for life science research. Various governments worldwide provide funding for research activities focused on biomarker discovery and precision medicine.
Economic: The rising per capita healthcare expenditure along with growing investment in R&D activities by pharmaceutical and biotechnology companies drives the market growth. High prevalence of cancer and other chronic diseases increases the demand for accurate diagnostics.
Social: Increasing awareness about early detection and diagnosis of diseases promotes the adoption of RNA markers. Advancements in personalized medicine enhances focus on disease profiling using biomarkers.
Technological: Continuous technological advancements in sequencing and data analysis aid discovery and validation of RNA-based biomarkers. Development of high-throughput techniques with automation improves workflow efficiency and diagnostic accuracy.
Key Takeaways
The global Ribonucleic Acid (RNA) Markers Market is expected to witness high growth.
Regional analysis: The North America region is expected to dominate the RNA markers market during the forecast period owing to the presence of major players and well-established healthcare infrastructure in the region. Key players operating in the RNA markers market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., QIAGEN, Promega Corporation, New England Biolabs, Bioline, Norgen Biotek Corp., and BioVision Inc.
Key players operating in the RNA markers market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., QIAGEN, Promega Corporation.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
About Author - Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn
